Personalis, Inc. (PSNL) vs Zenas BioPharma, Inc. (ZBIO)
A side-by-side comparison of Personalis, Inc. and Zenas BioPharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
PSNL
Personalis, Inc.
$15.92HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT
ZBIO
Zenas BioPharma, Inc.
$26.76HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT
Total return — PSNL vs ZBIO
growth of $100 · dividends reinvested · last 2yPSNL +197.1% (+72.4%/yr)ZBIO +54.9% (+24.4%/yr)PSNL compounded faster over this window
PSNL ZBIO
PSNL vs ZBIO: by the numbers
- •PSNL is the larger company ($1.70B vs $1.69B market cap).
- •Both run net losses; PSNL's is the smaller (-153.84% vs -48438.40% net margin).
Metrics side by side
Valuation
| Metric | PSNL | ZBIO |
|---|---|---|
| P/S ratio | 24.39 | 1689.56 |
| P/B ratio | 7.23 | 6.84 |
Profitability
| Metric | PSNL | ZBIO |
|---|---|---|
| Gross margin | 22.65% | 100.00% |
| Operating margin | -126.43% | -2113.85% |
| Net margin | -153.84% | -48438.40% |
| ROE | -45.58% | -196.03% |
| ROIC | -42.87% | -74.69% |
Growth (annualized)
| Metric | PSNL | ZBIO |
|---|---|---|
| Revenue CAGR (5Y) | -3.33% | N/A |
| Total return CAGR (5Y) | -1.75% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.